Immunotherapy and chemo with or without propranolol for colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding a blood-pressure medicine (propranolol) to a combination of two immunotherapy drugs plus chemotherapy is safe and works better for locally advanced colon cancer that has not spread. It's for tumors that are pMMR/MSS, which are less likely to respond to immunotherapy alone, so the propranolol may help the immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have colon cancer that has grown through the bowel wall (T4) or has spread to nearby lymph nodes (T3N+), but has not spread to distant organs.
- Your tumor must be at least 10 cm from the anus (about 4 inches up the colon).
- Your tumor must be 'pMMR' or 'MSS' — this is a test result from the biopsy that doctors check.
- You must not have had any previous treatment for this colon cancer (like chemo or surgery).
- Age between 18 and 75 years.
- You must be generally healthy with good organ function, controlled blood pressure, and normal thyroid levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding an immunotherapy drug (tislelizumab) and a probiotic to standard chemoradiation for locally advanced rectal cancer that has not spread. The goal is to see if the probiotic helps the treatment work better.
This trial tests adding a beta-blocker (propranolol) to a combination of immunotherapy (sintilimab) and standard chemotherapy for people with advanced non-small cell lung cancer that hasn't been treated before. The goal is to see if this new triple treatment helps shrink tumors better than chemo-immunotherapy alone.
This trial tests whether adding propranolol (a common blood-pressure/heart medicine) can improve outcomes when used with pembrolizumab plus standard chemotherapy. It is for people with advanced esophageal or gastroesophageal junction adenocarcinoma that cannot be removed with surgery.
This trial compares a standard chemotherapy combination (mFOLFOX6) plus a targeted drug (bevacizumab) with or without an immunotherapy (PD-1 antibody) for locally advanced colorectal cancer. It aims to see if adding the immunotherapy improves outcomes for patients with a specific tumor type (pMMR/MSS).
This trial tests whether giving radiation therapy along with standard chemotherapy before surgery can help shrink advanced colon cancer that has grown through the bowel wall but hasn't spread to other organs. It is for a specific type of colon cancer called pMMR/MSS.
This trial tests a new combination of two chemotherapy drugs (CAPOX) plus an immunotherapy drug (tislelizumab) before surgery for high-risk colon cancer that has not spread. It aims to see if adding tislelizumab helps shrink the tumor and lower the chance of the cancer coming back.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.